Use access key #2 to skip to page content.
$5.39 -0.09 (-1.64%)
5/16/2008 4:00 PM

Dendreon Corp (DNDN)

CAPS Rating:
**

A biotechnology company focused on the discovery, development and commercialization of novel therapeutics that harness the immune system to fight cancer.

Rating a stock in CAPS consists of three components:

Your call - Will this stock outperform or underperform the S&P 500? Successful picks are measured in terms of whether or not you were correct and by how many percentage points.

Your time frame - A guideline for other players to see whether your thinking is short or long-term. Time frame is also used to calculate the stock rating, but is not used in the scoring of your pick.

Your pitch - Here's your chance to offer more detailed thoughts, analysis, concerns, or the rationale behind your call. The pitch is optional and may be added later.

Each time you rate a stock, CAPS updates the community intelligence for the company, which may or may not change its CAPS rating. For more information, visit the Help tab at the top of the page.

You aren't currently rating DNDN

Add Stock to Watchlist

What the Community Thinks Add a widget featuring this stock to your blog!

Total Players

854 Outperforms
206 Underperforms
 

All-Stars

165 Outperforms
74 Underperforms
 

Wall Street

1 Outperforms
5 Underperforms
 

Players bullish on DNDN are also bullish on:

Players bearish on DNDN are also bearish on:

Ticker Tags

Biotechnology (291), Micro Cap (4824), Small Cap (1922), Rule Breakers Universe (161)
Suggest a tag

Dendreon Corp At A Glance

Current Price: $5.39
Last Trade Time: 5/16/2008 4:00 PM
Open: $5.55
Previous Close: $5.48
Daily Range: $5.31 - $5.56
52-Week Range: $4.15 - $13.00
Volume: 1,673,537
Market Cap: $510.71M
P/E Ratio: 0.00
Compare Our Special Broker Offers!

Stock Trends

DNDN VS S&P 500 (SPY)

DNDN 12 month chart vs. S&P

News & Discussion Boards

Other News Headlines for DNDN

More Headlines...

Top Bull Pitch

Recs

7

Dendreon Corp (DNDN)

Avatar tomk0508 (62.43) Submitted: 2/03/08 11:19 PM

This company is sitting on a blockbuster advance in treatment of late stage prostrate cancer. The compound is a biologic and therefore is a bit of a political football with the FDA. Fortunately, the drug is relatively harmless and very effective for cases that have been unresponsive to other treat...More

Replies: 0 | Reply | Permalink

Top Bear Pitch

Recs

2

Dendreon Corp (DNDN)

Avatar tharlow (< 20) Submitted: 8/14/07 12:36 AM

The ultimate placebo. Sugar tablets have never been so high-tech.

Replies: 0 | Reply | Permalink

CAPS Players

picks per page. CHANGE

Results 1 - 5 of 260 :   1 2 3 4 5 Next » Jump to page:

Recs

0

 (DNDN)

Avatar dinovaselino (< 20) Submitted: 5/15/08 5:32 PM : Underperform Start Price: $5.55 DNDN Score: 2.80

Spec. play on penny stock. Might be good for trading now while


waiting for more concrete news on FDA appoval. Might be a good


Idea to have some CEGE as well.

Report this Post Replies: 0 | Reply | Permalink

Recs

0

 (DNDN)

Avatar p50 (68.07) Submitted: 5/13/08 12:09 AM : Outperform Start Price: $5.12 DNDN Score: 3.66

to take the DNDN bet or not? FDA approval will make or break this stock!

Report this Post Replies: 0 | Reply | Permalink

Recs

0

 (DNDN)

Avatar deanafoulger (44.91) Submitted: 5/08/08 6:03 PM : Outperform Start Price: $5.06 DNDN Score: 3.44

This stock can be purchased at a great price and has the potential for great earnings. The company Dendreon is working to get a new drug approved for prostate cancer. It has already passed at least 3 FDA approvals.

Report this Post Replies: 0 | Reply | Permalink

Recs

0

 (DNDN)

Avatar Money2themax (61.58) Submitted: 5/07/08 12:28 AM : Underperform Start Price: $5.10 DNDN Score: -5.19

Another prostate cancer drug in the offing here. If the FDA approves-- this stock moves up and out! While we wait, this one fluctuates and doesn't do much.

Report this Post Replies: 0 | Reply | Permalink

Recs

0

 (DNDN)

Avatar socialistnyc (34.08) Submitted: 5/06/08 12:25 PM : Outperform Start Price: $5.08 DNDN Score: 5.21

How could you not root for a company that has developed a drug to fight prostate and breast cancer? They have been approved to sell their drugs in Europe and when the FDA approves them, they will skyrocket!

Report this Post Replies: 0 | Reply | Permalink

Results 1 - 5 of 260 :   1 2 3 4 5 Next » Jump to page:

Wall Street

Results 1 - 6 of 6  

picks per page. CHANGE

Top
Pick
Player NamePlayer RatingStart
Date
CallTime FrameStart
Price
Stock
Gain
S&P
Gain
ScorePitch
TrackJMP < 20 07/12/07 Underperform NS $7.88-31.60%-6.37%+25.23
TrackBreanMurray 88.12 05/11/07 Underperform NS $5.13+5.07%-4.73%-9.80
TrackBofASec 93.49 05/10/07 Underperform NS $5.75-6.26%-5.35%+0.91
TrackUBS 93.41 05/08/07 Underperform NS $17.14-68.55%-5.24%+63.31
TrackJimCramer 80.65 05/07/07 Underperform 3W $17.92-69.92%-5.49%+64.43
TrackNextGen < 20 05/03/07 Outperform NS $18.13-70.27%-4.90%-65.37

Results 1 - 6 of 6  

Beat this Stock

Clicking "Beat this Stock!" will bring you to a company with a higher rating than the one you're currently viewing.

Even though CAPS shows only one- to five-star rankings, behind the scenes, all companies in CAPS have a distinct numerical ranking. In other words, there is a No. 1 stock in CAPS and a worst-ranked stock in CAPS. When you arrive at the top-ranked stock, clicking "Beat this Stock!" will cause the page to refresh.

That is, until there is a new No. 1 stock!

These companies do not represent formal Motley Fool recommendations. Please do your own due diligence before investing. Fool on.

Featured Broker Partners